Publication

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Labrador, J., Luño, E., Vellenga, E., Brunet, S., González-Campos, J., Chillón, M. C., Holowiecka, A., Esteve, J., Bergua, J., González-Sanmiguel, J. D., Gil, C., Tormo, M., Salamero, O., Manso, F., Fernández, I., de laSerna, J., Moreno, M-J., Pérez-Encinas, M., Krsnik, I., Ribera, J-M., Cervera, J., Calasanz, M. J., Boluda, B., Sobas, M., Lowenberg, B., Sanz, M. A. & Montesinos, P., 16-Apr-2019, In : Leukemia & Lymphoma. 60, 5, p. 1146-1155 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Final publisher's version, 3.06 MB, PDF document

    Request copy

DOI

  • Jorge Labrador
  • Elisa Luño
  • Edo Vellenga
  • Salut Brunet
  • José González-Campos
  • Maria C Chillón
  • Aleksandra Holowiecka
  • Jordi Esteve
  • Juan Bergua
  • José D González-Sanmiguel
  • Cristina Gil
  • Mar Tormo
  • Olga Salamero
  • Felix Manso
  • Isolda Fernández
  • Javier de laSerna
  • María-José Moreno
  • Manuel Pérez-Encinas
  • Isabel Krsnik
  • Josep-Maria Ribera
  • Jose Cervera
  • María J Calasanz
  • Blanca Boluda
  • Marta Sobas
  • Bob Lowenberg
  • Miguel A Sanz
  • Pau Montesinos

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients with CK+, the 5-year CIR was 27% vs 12% (p=.003), retaining the statistical significance in multivariate analysis. This study shows an increased risk of relapse among APL patients with CK + treated with ATRA plus chemotherapy front-line regimens.

Original languageEnglish
Pages (from-to)1146-1155
Number of pages10
JournalLeukemia & Lymphoma
Volume60
Issue number5
Publication statusPublished - 16-Apr-2019

ID: 72489411